Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure - PubMed
3 hours ago
- #Cardiac Regeneration
- #Heart Failure Therapy
- #Stem Cell Research
- Study on stem-cell-derived biologic ventricular assist tissue (BioVAT) for cardiac remuscularization in heart failure patients with reduced left ventricular ejection fraction.
- Phase 1-2 open-label trial involving 20 patients; 16 received safe maximal dose with 12 completing 3-month follow-up.
- Primary results showed significant increases in target heart-wall thickness (4.5 mm) and left ventricular ejection fraction (3.9 percentage points), with slight improvement in KCCQ-OSS (6.7 points).
- Safety findings noted all patients experienced at least one adverse event, with three deaths (from vasoplegia, COVID-19, aortic dissection) and one heart transplantation.
- Conclusions support BioVAT's potential for improving cardiac function but highlight need for longer-term follow-up due to adverse events; funded by the German Center for Cardiovascular Research.